Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesTreatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Hernández-Rodríguez J et al. – The scarcity of randomized trials and the high level of heterogeneity of studies on PMR therapy do not allow firm conclusions to be drawn. However, PMR remission seems to be achieved with prednisone treatment at a dose of 15 mg/d in most patients, and reductions below 10 mg/d should preferably follow a tapering rate of less than 1 mg/mo. Methotrexate seems to exert glucocorticoid-sparing properties.
Methods- Searched Cochrane Databases and MEDLINE (1957 through December 2008) for English-language articles on PMR treatment (randomized trials, prospective cohorts, case-control trials, and case series) that included 20 or more patients
- All data on study design, PMR definition criteria, medical therapy, and disease outcomes using a standardized protocol
- 30 studies (13 randomized trials and 17 observational studies) analyzed
- No meta-analyses or systematic reviews found
- PMR definition criteria, treatment protocols, and outcome measures differed widely among trials
- Starting prednisone doses higher than 10 mg/d associated with fewer relapses and shorter therapy than were lower doses
- Starting prednisone doses of 15 mg/d or lower associated with lower cumulative glucocorticoid doses than higher starting prednisone doses
- Starting prednisone doses higher than 15 mg/d associated with more glucocorticoid-related adverse effects
Today in Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women: The Japanese Population-based Osteoporosis (JPOS) Cohort Study
Osteoporosis International, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor